Parkinson disease: Could over-the-counter treatment protect against Parkinson disease?

  title={Parkinson disease: Could over-the-counter treatment protect against Parkinson disease?},
  author={Carolyn Mcsharry},
  journal={Nature Reviews Neurology},
  • C. Mcsharry
  • Published 1 May 2011
  • Medicine, Psychology
  • Nature Reviews Neurology
In a large prospective study, Gao and his colleagues investigated the use of NSAIDs in 136,197 individuals from two cohorts— the Health Professionals Follow-up Study and the Nurses’ Health Study. All participants were free of PD at baseline, and were followed up for 6 years. During this time, 291 cases of PD emerged. Using questionnaires to obtain patients’ self-reported analgesic use, the researchers observed a dose–response relationship between the amount of ibuprofen taken PARKINSON DISEASE 
Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis
The CXCL13 ELISA and the CxCL13 LFA are comparable diagnostic tools for the detection of CXCl13 in the CSF of patients with definite LNB, and the advantage of the CXcl13 L FA is the shorter time to result.
Enhanced Longevity by Ibuprofen, Conserved in Multiple Species, Occurs in Yeast through Inhibition of Tryptophan Import
It is shown that ibuprofen increased the lifespan of Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila melanogaster, indicative of conserved eukaryotic longevity effects and points to fundamental cell cycle signatures linked with longevity.
Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.
Because antiinflammatory agents are already on the market, further clinical trials should be done to evaluate this effect in humans as soon as possible, to determine their suitability as coadjuvant tuberculosis treatment.


Use of ibuprofen and risk of Parkinson disease
The association between use of ibuprofen and lower PD risks, not shared by other NSAIDs or acetaminophen, suggests ib uprofen should be further investigated as a potential neuroprotective agent against PD.